Qiagen Says China Study Supports QuantiFERON-TB Gold Tuberculosis Test
This article was originally published in The Gray Sheet
Executive Summary
Results of a major trial in China show that results from traditional tuberculin skin tests often overestimate the prevalence of latent tuberculosis in China. Qiagen says the study supports screening high-risk populations with interferon-γ release assays like its QuantiFERON-TB Gold to reduce tuberculosis incidence.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.